Revenue on a disclosed basis fell from KRW 60.2 billion in 2022 to KRW 56.2 billion in 2023, a 6.6% decline, then rose to KRW 64.9 billion in 2024, up 15.3%, and to KRW 114.1 billion in 2025, up 75.9%. 2025 was the largest year of the 2022 to 2025 period.
Operating profit fell from KRW 8.87 billion in 2022 to KRW 1.3 billion in 2023, down 85.4%, then rose 259.2% to KRW 4.66 billion in 2024 and 636.8% to KRW 34.3 billion in 2025. Operating margin was 14.7% in 2022, 2.3% in 2023, 7.2% in 2024 and 30.1% in 2025. In 2025, operating profit growth far exceeded revenue growth.
The company attributes growth to electronic materials and raw materials such as nucleosides and mPEG. Net income attributable to controlling shareholders was KRW 10.9 billion in 2022, KRW 3.58 billion in 2023 (down 67.1%), KRW 6.33 billion in 2024 (up 77.0%) and KRW 40.3 billion in 2025 (up 536.3%).
In every year in the table, net income including non-controlling interests matches the figure attributable to controlling shareholders.
On a quarterly basis, revenue rose from KRW 25.6 billion in the third quarter of 2025 to KRW 34.6 billion in the fourth quarter, up 35.0% from the prior quarter, with operating profit of KRW 9.62 billion. Revenue was KRW 36.7 billion in the first quarter of 2026 and KRW 39 billion in the second quarter.
The third quarter of 2026 recorded revenue of KRW 37 billion, down 5.2% from the prior quarter, and operating profit of KRW 11.9 billion, down 9.8%. Operating cash flow was KRW 7.91 billion in 2022, KRW 12.9 billion in 2023, KRW 3.5 billion in 2024 and KRW 41.1 billion in 2025.
The debt ratio was 26.9% at the end of 2025, down from 41.4% in 2022. Total equity at the end of 2025 was KRW 123.9 billion, and total liabilities were KRW 33.3 billion.